Citations 1
Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802
Holtan, Shernan G. , Khera, Nandita , Levine, John E. , Lee, Stephanie J. , Inamoto, Yoshihiro , Mayer, Sebastian , Arora, Mukta , Palmer, Jeanne , Arai, Sally , Lazaryan, Aleksandr , Newell, Laura F. , Jagasia, Madan , Pusic, Iskra , Wood, William A. , Renteria, Anne S. , Yanik, Gregory A. , Ayuk, Francis , Holler, Ernst , Bunworasate, Udomsak , Efebera, Yvonne A. , Ferrara, James L.M. , Pidala, Joseph, Howard, Alan , Wu, Juan , Bolaños‐Meade, Javier , Ho, Vincent T. , Alousi, Amin, Weisdorf, Daniel J. , MacMillan, Margaret L. , Weisdorf, Dan , Levine, John E , Holtan, Shernan , DeFor, Todd E. , Panoskaltsis‐Mortari, Angela , Flowers, Mary E.D. , Chen, George L. , Cutler, Corey S. , Hogan, William J. , Hexner, Elizabeth O. , Howard, Alan, Alousi, Amin Majid , Blazar, Bruce R. , Lee, Stephanie J , Wood, William A
Blood Advances | August 28, 2018 | Volume: 2 | Issue: 15 | Pages: 1882-1888
10.1182/bloodadvances.2018017343
Key PointsHigh-circulating AREG (≥33 pg/mL) reclassifies additional patients into HR categories and further refines the Minnesota aGVHD risk score. Patients with aGVHD and AREG ≥33 pg/mL have lower rates of steroid response, higher NRM, and poorer OS.